In one study, Han et al. focused on PD-1+CD8+ T cells in patients with NSCLC, sequenced the complementarity determining region 3 of TCRβ chains and explored its predictive value in ICI therapy [34]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.